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Balb/c mice were immunized with rat striatal integral membrane proteins. After hybridization of splenocytes with myelo- 
ma cells, hybridoma lines secreting antibodies against serotonin, dopamine and opiate receptors were detected by inhibi- 
tion of ligand binding to brain membrane preparations. Antibodies from two positive lines, Mab/a9 and Mab/a 18, were 
able to inhibit ligand binding to the S:serotonin (Kd range: 10-100 nM), the g-opiate (Ka range: 0.4-3 gM) and the 
~-opiate receptors (Kd range: 0.7-I. 1 gM), while Mab/a9 was also found to inhibit ligand binding to the DJD4-dopamine 
receptor (Kd ~ 50 nM). An apparent molecular mass of 60 kDa could be ascribed to the c~-opiate r ceptor and apparent 
molecular masses of 29 and 36 kDa to the g-opiate receptor by ligand elution from immune-precipitates. 
Monoclonal antibody; Serotonin receptor; Dopamine receptor; Opiate receptor 
1. INTRODUCTION 
In v'~o binding studies and in vivo phar- 
/ 
macokinetics with various neurotransmitter 
agonists or antagonists [1-3] have indicated that, 
in general, neurotransmitters and their analogues 
are not strictly specific to a certain receptor. For 
example, serotonin acts on the Srserotonin recep- 
tors in nanomolar, but on the S2-serotonin recep- 
tors in micromolar concentrations, while spiperone 
shows nanomolar affinities for both the 
S2-serotonin and DJD4-dopamine receptors [2,3]. 
Similarly, opioids like etorphine and ketacocine 
recognize ~-,/z- and x-opiate receptors with com- 
parable affinities [4]. The opiate drug fentanyl 
binds to opiate receptors at nanomolar concentra- 
tions and to dopamine receptors at micromolar 
concentrations [3]. This range of specificities im- 
plies that similar structural domains presumably 
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prevail in the ligand-binding sites of neurotrans- 
mitter receptors. 
In the following, we present a study where 
monoclonal antibodies which were initially 
directed against he binding sites of the c~- and/z- 
opiate receptors were found to cross-react with 
S2-serotonin and D2/D4-dopamine r ceptors. 
2. MATERIALS AND METHODS 
2.1. Membrane preparation 
Crude synaptosomal membranes (P2m) were prepared from 
SPD rat brains or neuroblastoma x glioma NG108-15 cells [5]. 
Final membrane preparations were suspended in 50 mM Tris- 
HC1 buffer, pH 7.4 (Tris buffer) at 2 mg protein/ml. For im- 
munization (see below) P2m membranes from rat striatum were 
first treated with 0.1 M NaOH for removal of peripheral pro- 
teins [6]. 1 vol. pelleted membranes was resuspended in 9 vols 
ice-cold 0.1 M NaOH and immediately centrifuged at 25 000 × 
g (10 min, 4°C). The resulting pellet was then washed 3 times 
with Tris buffer at 4°C. About 90% of the membrane proteins 
were detached by this procedure and virtually no tubulin, actin 
or spectrin-like proteins remained in the membrane as indicated 
by SDS-polyacrylamide gradient gel electrophoresis (gradient: 
7.5-15%). The remaining membrane proteins were further 
fractionated according to molecular mass by preparative SDS- 
polyacrylamide g l electrophoresis with an intermediate agarose 
layer [7] as follows. The gel (approx. 15 cm) was divided into 
three layers (from bottom to top): (i) 2 cm of 20% 
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polyacrylamide, (ii) 2-3 cm of 1% agarose (in Tris buffer) and 
(iii) 5 cm of 60/0 polyacrylamide. Membrane proteins (2-5 rag) 
were dissolved in reducing sample buffer and loaded over the 
whole stacking el with the exception of one slot, which was 
reserved for the molecular mass markers (Sigma) labelled with 
fluorescamine (Sigma). Electrophoresis was carried out until 
fluorescamine-labelled carbonic anhydrase (29 kDa) entered the 
agarose layer. Proteins were recovered from the agarose by 
ultracentrifugation a d the remaining 6070 polyacrylamide gel 
was cut into two strips above fluorescamine-labelled bovine 
serum albumin. These strips were kept frozen at -20°C until 
use. Elution of the proteins in the remaining strips was carried 
out by a further gel electrophoresis. This gel consisted of the 
following layers (from bottom to top): (i) 2 cm of 200/0 
polyacrylamide, (ii) 2 -3cm of 1°70 agarose, (iii) 60/0 
polyacrylamide strip (upside down, i.e. higher molecular mass 
down), (iv) 2-3 cm of l°70 agarose, and (v) 6o70 polyacrylamide 
strip. Electrophoresis was carried out until the fluorescent 
markers passed the 6o7o polyacrylamide strips and elution from 
the 1 °70 agarose was carried out as above. Three fractions were 
obtained by this procedure: fraction I, <30 kDa; fraction II, 
30-66 kDa and fraction IIl, 66-300 kDa. In this study only 
fraction II was used for immunization. 
2.2. Immunization 
Balb/c mice (female; age, 12 weeks) were injected with 2 x 
50/A containing the sample (150/zg protein) in complete 
Freund's adjuvant. Identical injections were given in the front 
footpads 14 days later. After 6 weeks animals were injected in- 
traperitoneally on the sixth, fifth and fourth day before fusion 
with 200/zg protein dissolved in 100/zl Tris buffer [8]. 
2.3. Fusion 
Spleen cells (10 s ) obtained from two immunized mice, and 
2 x 107 NSO/I mouse myeloma cells were suspended in 3 ml 
DMEM (Dulbecco's modified Eagle's medium, supplemented 
with 1 mM sodium pyruvate, 4 mM L-glutamine, 500 U 
penicillin/ml and 1 pg fungizone/ml). Fusion was then induced 
by polyethylene glycol 1450 (Sigma), as described [8]. After 
resting for 2 days in DMEM supplemented with 15°/0 fetal calf 
serum, cells were diluted to a final concentration of 5 x 105 
cells/ml containing 1°70 agar (Difco), hypoxanthine (0.2/~M), 
aminopterin (1 nM) and thymidine (10 nM) and seeded on agar 
plates. About 1000 clones were transferred into Costar plates 
and screened for activity (see below). The positive hybridoma 
cell lines were propagated as either ascites or in vitro cell 
cultures [8]. 
2.4. Purification of monoclonal ntibodies 
Monoclonal antibodies from cell cultures or ascites were 
purified by anti-mouse antibody affinity chromatography 
(Sigma). 0.1 M glycine-HCl, pH 2.7, was used as an elution 
buffer [8]. The isolated antibodies were then dialyzed against 
the appropriate buffer after neutralization. 
2.5. Screening assay 
Decrease in total igand binding to a specific neurotransmitter 
receptor was used as an indication for th.e presence of anti- 
receptor antibodies in the hybridoma supernatants. The follow- 
ing radioactive ligands were used: [3H]morphine (79.2 Ci/mol, 
NEN) for the /z-opiate receptor [4], [3H](D-AIa-Met)- 
enkephalinamide (39.4 Ci/mol, NEN) for the 5-opiate receptor 
[4[, and [3H]spiperone (31.7 Ci/mol, NEN) for the S2-serotonin 
and Dz/D4-dopamine r ceptors [2,3,10]. The assays were car- 
ried out as follows: Membranes (P2m) from rat striatum (300 pg 
protein in 100/Ll Tris buffer) were incubated with 300/zl super- 
natant from hybridoma cultures for 1 h at 25°C. Samples were 
then cooled to 4°C, supplemented with 300/zl ice-cold Tris buf- 
fer and centrifuged for 10 rain (2000 x g, 4°C). Pellets were 
resuspended in 300/zl Tris buffer supplemented with 1 mM 
EDTA and transferred to microtiter plates (Falcon 4075). Tris 
buffer (50/~l) containing the radioactive ligand was added to a 
final concentration of 10 nM for [3Hl(D-Ala2-MetS)- 
enkephaiinamide, and 5 nM for [~H]morphine and [3H]spiper- 
one. Bound ligand was separated from free by filtration 
(Scatron cell harvester) through Whatman glass fiber filter 
(934-AH) after 8 rain incubation at 25°C. Membranes were 
then washed for 5 s with ice-cold Tris buffer. After drying, 3 ml 
Lumax was added to scintillation vials containing the filters. 
Radioactivity was measured after 12 h. 
2.6. Receptor assay 
Binding assays were performed according to [2,3,9,10]. Pro- 
tein concentration was determined colorimetrically [11]. The 
concentrations u ed for inhibition studies, were 3 nM [3H](D- 
Ala2-MetS)-enkephalinamide, 1 nM [3H]dihydromorphine (90.0 
Ci/mmol, NEN) and [3H]spiperone (31.7 Ci/mmol, NEN). 
Non-specific binding was determined using 1/ZM levallorphan 
for the 6- and/z-opiate receptors, 1/ZM mianserin for S2-sero- 
tonin receptors and 1/ZM haloperidol for D2/D4-dopamine 
receptors. 
2.7. Immuno-precipitation 
Membranes ( -10rag P2m from whole rat brain minus 
cerebellum) were solubilized with 5 ml of 10 mM Chaps/Tris 
buffer, pH 7.4 [12[. After ultracentrifugation (1 h, 120000 x g, 
4°C), aliquots of 1 ml supernatant were incubated in 1.5-ml Ep- 
pendorf tubes with 0.7-1/~M monoclonal antibodies (Mab/a9 
or Mab/al8) for 30 rain at room temperature and an additional 
30 rain in the presence of 40/zl insoluble protein A (Sigma). The 
receptor-monoclonai antibody-protein A complex was washed 
4 times with ice-cold 2 mM Chaps/Tris buffer, pH 7.4. Elution 
of bound receptors was carried out with 1 nM (D-Ala2-LeuS) - 
enkephaiinamide (Sigma) for the d-opiate receptor [10] or 1 nM 
(D-AlaZ,N-Me-Phe4,Met(O)S-ol)-enkephalin for the /z-opiate 
receptor [10]. 
2.8. Radio-iodination of putative opiate receptors 
Proteins, obtained by immuno-precipitation, were iodinated 
with 125I by the chloramine T method [13] and separated from 
free ~2sI by size-exclusion chromatography (Sepharose G-25 
fine, Pharmacia) using 0.01°70 SDS in H20 as eluant. After 
SDS-polyacrylamide gradient (7.5-1507o) gel electrophoresis 
[14], radioactive proteins were visualized by autoradiography 
(Agfa-Gevaert, Curix RP2 X-ray film). 
3. RESULTS 
St r ia ta l  ra t  membranes ,  enr iched  w i th  in tegra l  
p ro te ins ,  were prepared  by  mi ld  a lka l ine  t reatment  
to  remove pract ica l ly  al l  per iphera l  p ro te ins  [6]. 
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About 90070 of the protein content was removed by 
this procedure. Fractionation by preparative gel 
electrophoresis resulted in an additional 3-fold 
enrichment. Fraction II (Mr 30000-66000), which 
presumably contained the ~- and/z-opiate r ceptors 
[15-17], was then used for immunization. About 
1000 hybridoma clones were then produced and 
their antibodies were screened for decrease in total 
receptor-ligand binding. The employed ligands 
were [3Hl(D-Ala-Met)-enkephalinamide for the ~- 
opiate receptor, [3H]morphine for the /z-opiate 
receptor and [3H]spiperone for S2-serotonin and 
Dz/D4-dopamine r ceptors. 
Since optimal binding of these ligands requires 
special media (e.g. absence of Na + for binding of 
opiate agonists), it was not possible to incubate 
simultaneously ligands and the supernatants of the 
hybridoma cultures with membrane receptor 
preparations. The assay, therefore, consisted of 
first reacting the membranes with the antibody, 
followed by exchanging the incubation media (ap- 
propriate for ligand binding) and immediate in- 
cubation with the radioactive ligand. Bound 
antibody continuously dissociates under these con- 
ditions. We estimated that antibodies with 
dissociation constants lower than 5/zM could be 
detected by inhibition of ligand binding within ap- 
prox. 10 min of the second incubation. In order to 
achieve such a high rate of ligand association, 
membrane receptor concentrations as well as 
ligand concentrations were relatively high (see sec- 
tion 2.5) and the binding assay was performed at 
25°C instead of 4°C. Under such conditions 
saturation isotherms were reached after 8 min in- 
cubation (not shown). The timing of the second in- 
cubation (8 min) was a critical parameter and, 
therefore, accurately maintained. 
Employing this screening procedure, several 
hybridoma lines were found to secrete antibodies 
which inhibit serotonin, dopamine and opiate 
receptor binding. Monoclonal antibodies from two 
clones, Mab/a9 and Mab/alS, were studied in 
more detail. Mab/a9 and Mab/al8 could inhibit 
ligand binding to the S2-serotonin, as well as to the 
~- and/z-opiate receptor (figs 1,2) at nanomolar 
and micromolar concentrations, respectively (table 
1). Mab/18 did not inhibit D2/D4-dopamine 
binding, while Mab/a9 was able to displace 
[3H]spiperone binding with an apparent Kd of 
about 50 nM (fig.l, table 1). Other 3H-labelled 
. . . . . . .  'I ' ' " , '" I  , ','"I , , ',,',, 
80 
~60 o 
'~  40  mmm 
20 
0 l:l • - 
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10 9 I0" 16 7 10 6 10 5 
Mob/og(molor) 
Fig. 1. Inhibition of receptor ligand binding by Mab/a9. Pzm 
membranes from whole rat brain minus cerebellum were first 
incubated with increasing amounts of Mab/a9 antibodies and 
then with either 3 nM [3H](D-Ala-Mct)-cnkephalinamide (e), 
I nM [3H]dihydromorphine (o), a mixture of i nM 
[3H]spipcrone and !/zM mianserin (o)  or a mixture of ! nM 
[3H]spiperone and !/~M halopcridoi (B) as described in section 
2.5. 
ligands, like [3H]naloxone (opiate antagonist) [4], 
3H]dipremorphine (x-opiate agonist) [18] and 
[3H]serotonin (Sl-serotonin agonist) [2], could not 
be displaced by Mab/a9 or Mab/al8 up to final 
antibody concentrations of 10/zM (table 1). 
Inhibition curves of [3H](D-Ala-Met)-enkepha- 
linamide and [3Hldihydromorphine binding (figs 
1,2) were used to define the appropriate concentra- 
tion of monoclonal antibodies for subsequent 
analysis of the mode of inhibition (i.e. competitive 
or non-competitive) according to Scatchard [19]. 
IOO 
80 
C 
~ 60 
.13 
~ 20 
o 
16 s
. . . . . . . .  l , .~ . . . . . .  l . . . . . . . .  
g. 
Mob/o18(molor) 
Fig.2. Inhibition of receptor-ligand binding by Mab/al8. P,m 
membranes from whole rat brain minus cerebellum were first 
incubated with increasing amounts ofMab/al 8 antibodies and 
then with either 3 nM [3H](D-Ala-Met)-enkephalinamide (e), 
1 nM [3H]dihydromorphine (o), a mixture of 1 nM 
[3H]spiperone and 1/~M mianserin (-), or 1 nM [3H]spiperone 
(o). 
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Table 1 
Binding characteristics of monoclonal antibodies Mab/a9 and 
Mab/a 18 
Opiate receptors Serotonin and 
dopamine 
J /z ~ receptors 
Kd Mode Kd Mode $2- D2/ 
~M) ~M) type D4 
Kd Kd 
(nM) (nM) 
Mab/a9 0.7 c. 2.9 nc. nb. - 10 -50  
Mab/al8 1.1 nc. 0.4 c. nb. -60  nb. 
Kd, apparent dissociation constant; c., competitive binding; 
nc., non-competitive binding; nb., no binding (Kd > 10/ZM) 
The results, presented in figs 3 and 4 and Sum- 
marized in table l, indicate that Mab/a9 binds 
non-competitively to the/z-opiate r ceptor with an 
apparent Kd of 2.9/zM and competitively to the 3- 
opiate receptor with an apparent Kd of 0.7/zM. 
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Fig.3. Mode of Mab/a9 binding to the J-opiate receptor. (A) 
Binding curve of [3H](D-Ala-Met)-enkephalinamide ([3H]- 
DAMEA). P2m membranes from whole rat brain minus 
cerebellum and increasing amounts of [3H](D-Ala-Me0- 
enkephalinamide w re incubated with (o) and without (e) 
3/zM Mab/a9. (B) Scatchard analysis of the above data. 
~ 3O ._c 
o 
o, 20 
E 
2[ 
so 
E 3G 
~ 2c 
-.~ I( 
I I i i 
I I I I 
0.2 3 0.4 0.6 0.8 1.0 
H- Dihydromor phine(nm) 
,2, 
10 20 30 40 50 
Bound (f tool/rag prote in )  
Fig.4. Mode of Mab/a9 binding to the/z-opiate r ceptor. (A) 
Binding curve of [3H]dihydromorphine. P2m membranes from 
whole rat brain minus cerebellum and increasing amounts of 
[3H]dihydromorphine were incubated with (o) and without (e) 
2 aM Mab/a9. (B) Scatchard analysis of the above data. 
Conversely, Mab/a18 binds competitively tothe/z- 
opiate receptor with an apparent Kd of 0.4/ZM and 
non-competitively to the 3-opiate receptor with an 
apparent Kd of 1.1/ZM. 
The monoclonal antibodies Mab/a9 and 
Mab/al8 could provide a means for the isolation 
and characterization of the S2-serotonin and 
D2/D4-dopamine r ceptors as well as the 3- and/z- 
opiate receptors. Among these receptors, only the 
3- and the/z-opiate r ceptors have been characteriz- 
ed thus far with respect o their molecular mass 
[15-17]. It was, therefore, decided to concentrate 
in this study on the opiate receptor. Opiate recep- 
tors were solubilized in an active form and im- 
munoprecipitated (see section 2.7). The 3-opiate 
agonist (D-AlaE-LeuS)-enkephalinamide and /z- 
opiate agonist (D-Ala2,N-Met-Phe4,Met(O)5-ol) - 
enkephalin were then used to dissociate the respec- 
tive receptor from the immuno-precipitate with 
Mab/al8. The proteins in the supernatant were 
radio-iodinated and analyzed by SDS gel elec- 
trophoresis ( ee section 2.8). The autoradiograms 
revealed three bands of apparent molecular masses 
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60, 39 and 29 kDa with either one of the opiate 
agonists (not shown). In an analogous experiment, 
a single protein band with an apparent molecular 
mass of 60 kDa was identified with membranes of 
neuroblastoma x glioma (NG108-15) cells. Since 
these cells are known to contain J-opiate, but not 
/z-opiate receptors [16], this protein band could be 
attributed to the J-opiate receptor in agreement 
with the results of Simonds et ai. [15,16], who ob- 
tained a value of 58 kDa for the molecular mass of 
this receptor by affinity labelling. The remaining 
species (36 and 29 kDa) might be tentatively at- 
tributed to the/z-opiate receptor [17]. 
4. DISCUSSION 
Despite the great demand for monoclonal an- 
tibodies against membrane receptors, their produc- 
tion has been successful in only a few cases [20,21]. 
The major obstacle in the preparation of 
monoclonal antibodies for the dopamine, 
serotonin or opiate receptors is undoubtedly their 
minute amount in biological tissues. Here, instead 
of  using purified receptors, we have used enriched 
receptor preparations for immunizations. The 
screening method for positive clones was based on 
inhibition of receptor ligand binding. The 
monoclonal antibodies of 2 positive clones, 
Mab/a9 and Mab/a lS ,  were studied in detail and 
their basic characteristics are listed in table 1. Both 
antibodies were found to display high affinities for 
the S2-serotonin receptor and low affinities for the 
J- and/z-opiate receptors. Mab/a9 was also found 
to inhibit ligand binding to the D2/Da-dopamine 
and S2-serotonin receptors with similar affinities 
(figs 1,2). 
Since data on molecular masses for the J- and/z- 
opiate receptors are now available [15-17], we 
have investigated the purification potential of our 
monoclonal antibodies with these receptors. Three 
protein bands of 60, 36 and 29 kDa were identified 
after immuno-precipitation with Mab/a lS.  In 
agreement with other studies, the first could be at- 
tributed to the J-opiate receptor [15,16] with the 
other two being ascribed to the/z-opiate receptor 
[17]. With respect o the latter, Bidlack and Den- 
ton [17] reported an apparent molecular mass of 
35 kDa for the /z-opiate receptor, which was 
isolated by monoclonal antibody affinity 
chromatography [17]. In their study, however, a 
pre-purified mixture of proteins, and not a whole 
membrane xtract, was used for affinity purifica- 
tion. Therefore, it is possible that the missing 
29 kDa protein has been overlooked and, in this 
context, it should be noted that binding studies 
have indeed indicated the existence of multiple/z- 
opiate receptors [22]. The two species (36 and 
29 kDa) identified in our study may therefore 
represent the/Zl- and/z2-opiate r ceptors, an assign- 
ment which remains to be verified by further ex- 
periments. 
The cross-reactivities of Mab/a9 and Mab/a l8  
between S2-serotonin, D2/D4-dopamine, as well as 
J- and/z-opiate receptors, reflect a certain struc- 
tural homology in the ligand-binding site of these 
receptors. This homology might be implicated in 
basic processes of neurotransmission. 
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